Rigel Pharma Does Not Expect To File SNDA For Fostamatinib For Treatment Of WAIHA
WASHINGTON (dpa-AFX) - Shares of Rigel Pharmaceuticals, Inc. (RIGL) are slipping over 11% in extended session on Monday after the…
0,892€
1,59%
Echtzeit-Aktienkurs Rigel Pharmaceuticals
Bid:
Ask:
Nachrichten zur Rigel Pharmaceuticals Aktie
Rigel Pharma Shares Fall 16% After FDA Guidance on wAIHA Treatment
Rigel Pharma Shares Fall 16% After FDA Guidance on wAIHA Treatment...…
Rigel Provides Update on Plans for sNDA for wAIHA Program Following FDA Feedback
--Announces Workforce Reduction-- SOUTH SAN FRANCISCO, Calif., Oct. 10, 2022 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that…